相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study
Richard J. Nowak et al.
NEUROLOGY (2022)
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis The RINOMAX Randomized Clinical Trial
Fredrik Piehl et al.
JAMA NEUROLOGY (2022)
High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis
Akiyuki Uzawa et al.
JOURNAL OF NEUROIMMUNOLOGY (2021)
Sustained Systemic Levels of IL-6 Impinge Early Muscle Growth and Induce Muscle Atrophy and Wasting in Adulthood
Laura Pelosi et al.
CELLS (2021)
Advances and challenges in the treatment of myasthenia gravis
Christiane Schneider-Gold et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
Pushpa Narayanaswami et al.
NEUROLOGY (2021)
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
Susanna Brauner et al.
JAMA NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
Ennio G. Favalli
RHEUMATOLOGY AND THERAPY (2020)
Immunotherapy choice and maintenance for generalized myasthenia gravis in China
Chao Zhang et al.
CNS NEUROSCIENCE & THERAPEUTICS (2020)
Understanding the burden of refractory myasthenia gravis
Christiane Schneider-Gold et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Measuring Clinical Treatment Response in Myasthenia Gravis
Carolina Barnett et al.
NEUROLOGIC CLINICS (2018)
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
Renato Mantegazza et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab
Dagur Ingi Jonsson et al.
NEUROMUSCULAR DISORDERS (2017)
Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China
Lei Zhou et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2017)
Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
Zhen Wang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Future perspectives in target-specific immunotherapies of myasthenia gravis
Marinos C. Dalakas
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
Marie Maurer et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2015)
A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
Toshio Tanaka et al.
SEMINARS IN IMMUNOLOGY (2014)
Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis
Revital Aricha et al.
JOURNAL OF AUTOIMMUNITY (2011)
Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production
CS Deng et al.
JOURNAL OF IMMUNOLOGY (2002)